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The skin is the largest organ of the human body and its main functions include
providing protection from external harmful agents, regulating body temperature, and
homeostatic maintenance. Skin injuries can damage this important barrier and its
functions so research focuses on approaches to accelerate wound healing and
treat inflammatory skin diseases. Due to their regenerative and immunomodulatory
properties, mesenchymal stromal cells (MSCs) have been reported to play a significant
role in skin repair and regeneration. However, it seems that the secretome of these cells
and exosomes in particular may be responsible for their functions in skin regeneration
and the immunomodulation field. The present review aims to gather the available
information about the role of MSC-derived exosomes for both in vitro and in vivo models
of different skin conditions and to highlight the need for further research in order to
overcome any limitations for clinical translation.
Keywords: exosomes-based therapy, immunomodulation, mesenchymal stem cell-derived exosomes,
regenerative medicine, skin autoimmune diseases, skin wound healing
INTRODUCTION
The skin is the largest organ of the human body and constitutes a protective barrier that isolates us
from harmful agents and injuries. Apart from its defensive function against physical, chemical, and
biological agents, the skin also contributes to regulating the organism’s temperature, homeostatic
maintenance, participation in the mechanisms of sensorial perception, as well as in regenerative
processes (Oualla-Bachiri et al., 2020; Sanabria-de la Torre et al., 2020).
The skin is frequently damaged as a result of acute and chronic wounds such as extensive
burns, trauma or diabetic ulcers and also because of other conditions like atopic dermatitis (AD),
aging or oxidative stress (Cho et al., 2018; Lai et al., 2018; Roşca et al., 2018; Casado-Díaz et al.,
2020; Zhang Y. et al., 2020). Patients with cutaneous wounds experience physical and mental
health problems, and these wounds also have a huge socioeconomic burden (Wu et al., 2018).
Recently, mesenchymal stromal cells (MSCs) have gained much attention in cutaneous repair
and regeneration. Resident skin MSCs are actively involved in the wound-healing process, either
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by differentiating into fibroblasts, which are responsible for the
matrix synthesis, or through the release of various molecules
involved in tissue regeneration, such as anti-scarring, anti-
apoptotic and pro-angiogenic factors. Thus, the paracrine activity
of resident and recruited cells effects the suitability of the
regenerative process (Ballini et al., 2018). In fact, several studies
have applied exogenous MSCs to wounds in order to benefit
from their regenerative properties, resulting in positive effects
on both wound healing and scarring (Roşca et al., 2018). This
therapeutic potential of MSCs is mainly due to their facility to
be isolated and expanded in vitro and the possibility of being
cryopreserved once isolated, without significant loss of their
potential. Furthermore, MSCs are hypoimmunogenic since these
cells express intermediate or low levels of the MHC class I and
II molecules respectively (Casado-Díaz et al., 2020). MSCs can
be isolated from different tissues, although the most widely used
are bone marrow-derived MSCs (BM-MSCs), adipose tissue-
derived MSCs (AT-MSCs), and umbilical cord-derived MSCs
(UC-MSCs). Another promising source of MSCs is the oral
cavity, including tissues such as dental pulp, human periapical
inflamed cyst, dental pulp of human exfoliated deciduous teeth,
periodontal ligament, dental follicle progenitors, root apical
papilla of human teeth and gingiva (Spagnuolo et al., 2018).
Moreover, MSCs have been isolated from other regions such
as amniotic fluid, the periosteum and fetal tissues, all of which
show phenotypic heterogeneity (Hoang et al., 2020). They
can also be extracted from the blood, liver, spleen, and bone
marrow of the human fetus in the first and second trimesters
(Hoang et al., 2020).
However, despite the significant progress which has been
made in the application of MSCs in wound repair and cutaneous
regeneration, there are some limitations inherent to MSC cell
therapy. For instance, there is considerable heterogeneity in
the delivery protocols and MSC populations which makes it
difficult to determine the impact of timing of delivery, number
of cells produced and site of delivery on MSCs. In addition,
there is no evidence that MSCs differentiate into phenotypes
typical of resident cutaneous cells during skin wound healing
(Hu et al., 2019). Lastly, current challenges for the use of
MSCs concern the lack of universally accepted criteria for
defining the MSC phenotype and their functional properties.
Actually, MSCs mediate distinct immune modulating responses
that are characterized by a pro-inflammatory MSC1 phenotype
and an immunosuppressive MSC2 phenotype (Lai et al.,
2018). Other limitations include their proliferation capacity,
lifespan, potential contamination by handling and rejection
(Ferreira and Gomes, 2019).
There is current evidence that MSCs achieve a therapeutic
effect in vivo mainly through paracrine signaling (Wu et al., 2018;
Hu et al., 2019; Casado-Díaz et al., 2020) and not only due to
their capacity to proliferate and differentiate into the required
cellular types in the damaged tissue but also because of their
secretome (Ballini et al., 2017). The MSC– secretome has one free
fraction, made of soluble factors and metabolites, and another
encapsulated into extracellular vesicles (EVs).
Extracellular vesicles are typically classified into three
subtypes according to size and biogenesis mechanisms: exosomes
(50–100 nm), microvesicles (100–1000 nm), and apoptotic
bodies (500–5000 nm) (Qiu et al., 2019). Exosomes are
generated through endocytosis, from larger intracellular vesicles
called multivesicular bodies (MVBs) through a sophisticated
intracellular trafficking system (Aheget et al., 2020). MVBs
are intraluminal vesicles, formed by internal budding of the
endosomal membrane. The best-known mechanism of MVB
and exosome generation is that carried out by the endosomal
sorting complex required for transport (ESCRT), although other
mechanisms such as hydrolysis of sphingomyelin into ceramides
or proteins like tetraspanins have been reported (Andreu and
Yáñez-Mó, 2014). MVBs migrate toward the edge of the cell
where they fuse with the plasma membrane and exosomes are
then released to the extracellular space via exocytosis (Qiu et al.,
2019; Casado-Díaz et al., 2020). Thus, exosome biogenesis can
be divided into three stages: the formation of endocytic vesicles,
through the invagination of the plasma membrane; the formation
of MVBs, by the inward budding of the endosomal membranes;
and the fusion of MVBs with the plasma membrane and
exosome release (Casado-Díaz et al., 2020). In addition to MSC
surface antigens such as CD90, CD73, and CD105, exosomes
have multiple specific marker proteins, including membrane
transport and fusion proteins (GTPases, annexins, and flotillin),
tetraspannins (CD9, CD63, and CD81), heat shock proteins
(hsp60, hsp70, and hsp90), proteins involved in MVB biogenesis
(Alix and tumor susceptibility gene 101 protein), as well as lipid-
related proteins and phospholipases (Liu et al., 2018; Ferreira and
Gomes, 2019; Casado-Díaz et al., 2020).
Exosomes are key bioactive vesicles responsible for the
paracrine effects of MSCs, regulating many physiological and
pathological processes by affecting the survival, proliferation,
migration and gene expression of recipient cells and by
reprogramming targeted cell behaviors (Wu et al., 2018). Several
studies have indicated that some exosomes are involved in the
skin’s physiological and pathological processes (Liu et al., 2018).
Compared to MSC therapy, MSC exosomes have the following
advantages: Firstly, MSC exosomes exert intense biological effects
because of their direct fusion with target cells. Secondly, MSC
exosomes can be stored and transported at −70◦C for long
periods of time since their effective components are protected by
their membrane, which is not easily destroyed (Zhao et al., 2017).
Thirdly, the concentration, dose, route and time of use are easy
to control. Lastly, there is no risk of the immune rejection and
tumorigenesis caused by cell transplantation therapy (Hu et al.,
2019; An et al., 2020; Yu et al., 2020). In addition, exosomes
can be sterilized by filtration during their preparation for clinical
usage (Lai et al., 2018). Regarding exosome administration
routes, the most common are intravenous and subcutaneous
injections although they can also be administered through
biocompatible scaffolds or hydrogels, which can serve as
sustained release systems for these vesicles (Wang C. et al., 2019;
Yang J. et al., 2020).
Due to the current interest in the potential therapeutic
applications of MSC-derived exosomes, the main objective of the
present review is to analyze their role in dermatology, focusing
on wound healing and skin regeneration, GVHD, AD, psoriasis,
photoaging, oxidative stress, and rejuvenation (Figure 1).
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FIGURE 1 | Role of MSC exosomes in dermatology. Exosomes are widely isolated through MSC culture media ultracentrifugation (Gardiner et al., 2016) although
other isolation methods such as commercial kits, polyethylene glycol/polymer-based EV enrichment and size-based fractionation have been described (Witwer et al.,
2019). The presence of MSC exosome markers can be analyzed by methods including Western blotting, enzyme-linked immunosorbent assays, classical flow
cytometry of bead-captured EVs, or advanced flow cytometry at the single EV level. The main signaling pathways and proteins involved in the role of MSC exosomes
are highlighted. Created with BioRender.com.
EXOSOMES AND WOUND HEALING
Cutaneous wound healing is a complex, dynamic process in
charge of restoring the structure and function of damaged tissues.
It involves highly orchestrated multiple processes including
hemostasis, inflammation, cell migration and proliferation,
angiogenesis and extracellular matrix remodeling (Lai et al., 2018;
Gao et al., 2020) which are strictly regulated by multiple diverse
growth factors, cytokines, enzymes and structural matrix proteins
generated by multiple cell types such as dermal fibroblasts,
epidermal keratinocytes, and immune cells (Zhao et al., 2017;
Hoang et al., 2020). Among the varied factors influencing
wound repair, angiogenesis occupies a critical position, which
results in the delivery of nutrients and oxygen to the wound
sites, promoting fibroblast proliferation, collagen synthesis, and
re-epithelialization (Liu et al., 2020; Yu et al., 2020). Under
pathological conditions, the disruption and prolonging of the
wound-healing process can lead to chronic, non-healing wounds
such as diabetic wounds (Liu et al., 2020). The mechanisms
underlying poor healing of diabetic wounds are still unclear
although the main complications involve hypoxia, impaired
angiogenesis, damage from reactive oxygen species (ROS)
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and neuropathy, leading to long-term medical burden and
compromised quality of life in those patients (Wang C. et al.,
2019; An et al., 2020).
Another problem associated with impaired wound healing
is scarring. Cutaneous scar formation is a consequence of
the wound-healing process and involves the coordination
of a complex sequence of interactions between cells, ECM
components and signaling molecules. Scar tissue is characterized
by the exaggerated deposition of ECM components and a
lack of skin appendages such as hair follicles and sweat
glands. ECM remodeling, especially collagen synthesis and
degradation, is the key cellular and molecular event contributing
to scarring. Furthermore, the fibroblast-myofibroblast transition
is critical in this process. In response to skin injury and wound
damage, dermal fibroblasts undergo a phenotype transition into
myofibroblasts, characterized by enhanced contractile ability and
the expression of α-smooth muscle actin (α-SMA). Moreover,
several studies have stated that the Transforming Growth Factor
(TGF)-β1/Smad signaling pathway actively takes part in collagen
formation and the fibroblast-myofibroblast transition (Wang
et al., 2017). Interestingly, scarless healing occurs in the early
or midgestation stages of embryonic development. Thus in fetal
wound tissue, the ratio of collagen type III to type I is higher
and there is also a higher ratio of TGF-β3 to TGF-β1 and
of matrix metalloproteinases (MMPs) to tissue inhibitors of
metalloproteinases (TIMPs).
Therapies based on MSCs showed great potential for
wound healing due to their ability to recruit cells and
release growth factors and proteins. In fact, MSCs have been
tested as a promising cell-based therapy for diabetic wounds
in vitro and in vivo because of their ability to accelerate
wound closure with increased epithelialization, granulation
tissue formation, and angiogenesis by differentiation into skin
cells and paracrine pathways to repair injured cells. However,
due to the disadvantages of MSCs, more efforts have been
focused on the MSC secretome including cytokines, growth
factors, chemokines and extracellular vesicles containing mRNA,
proteins and microRNAs, as well as their role on the wound-
healing process (An et al., 2020).
Mesenchymal stromal cell-derived exosomes can promote
angiogenesis, cell migration, proliferation and the re-
epithelialization process by activating a signaling route such
as the Wnt/β-catenin, phosphatidylinositol 3-kinase/protein
kinase B pathway (PI3K/AKT) or extracellular signal-regulated
kinase (ERK) cascade, resulting in growth factors expression
upregulation (Carrasco et al., 2019; Kucharzewski et al., 2019).
For instance, exosomes isolated from human AT-MSCs
(hAT-MSCs) stimulate cell proliferation and migration and
play an inhibitory role in the cell apoptosis of in vitro
cultured human keratinocytes (HaCaTs) treated with hydrogen
peroxide (H2O2) through Wnt/β-catenin signaling (Ma et al.,
2019). Metastasis Associated Lung Adenocarcinoma Transcript
1 (MALAT1), a transcriptional regulator for numerous genes
contained in these exosomes, can also mediate H2O2-induced
wound healing by targeting miR-124 and activating this pathway
(He et al., 2020). Zhang et al. showed that 14-3-3ζ protein in
human UC-MSC (hUC-MSC) derived exosomes enhances the
Hippo/Yes-associated protein (YAP) pathway, promoting self-
regulation of Wnt/β-catenin signaling at the remodeling phase
of cutaneous regeneration in vivo and restricting excessive skin
cell expansion and collagen deposition 4 weeks after treatment
in a rat deep second-degree burn model (Zhang et al., 2016).
They found that exosomal 14-3-3ζ promoted the binding of
p-LATS (large tumor suppressor) and YAP at high cell density,
resulting in phosphorylation of YAP. Interestingly, miR-135a-
mediated downregulation of large tumor suppressor 2 (LATS2)
increased the migration of BJ cells in vitro and promoted wound
healing in vivo (Gao et al., 2020). Regarding Wnt/β-catenin
signaling, Wnt4 contained in hUC-MSC-derived exosomes
promoted β-catenin nuclear translocation and activity to enhance
proliferation and migration of HaCaTs in vitro and played a key
role in wound re-epithelialization in a rat skin burn model in vivo
(Zhang et al., 2015a). β-catenin nuclear translocation induced
the increased expression of proliferating cell nuclear antigen
(PCNA), cyclin D3, N-cadherin and β-catenin and the decreased
expression of E-cadherin. Furthermore, Wnt4 induces β-catenin
activation in endothelial cells and exerts proangiogenic effects
in vitro, which could be an important mechanism for cutaneous
wound healing (Zhang et al., 2015b). Other proliferative markers,
growth factors and migration-related chemokines such as
angiotensin-2 (Ang-2) (Liu et al., 2020), cyclin D1, cyclin A2
and C-X-C motif chemokine 12 (CXCL12) were significantly
upregulated after hUC-MSCs-derived exosome treatments with
human umbilical vein endothelial cells (HUVECs) in vitro,
promoting proliferation, migration and angiogenesis (Li X.
et al., 2020). In this study, in vivo administration of iron
oxide nanoparticle-labeled exosomes significantly increased the
number of exosomes accumulated at the injury site, enhancing
endothelial cell proliferation, migration and angiogenic tubule
formation as well as reducing scar formation due to the increased
expression of CK19, PCNA, and collagen.
Another important signaling route in the wound-healing
process, parallel to the Wnt/β-catenin pathway, is PI3K/AKT.
Yang C. et al. (2020) reported that miR-21 packaged in hAT-MSC-
derived exosomes enhances MMP-9 expression and decreases
TIMP-1 through the PI3K/AKT pathway, promoting the
proliferation of HaCaTs in vitro. Moreover, miR-126-mediated
phosphatase and tensin homolog (PTEN) downregulation seems
to stimulate angiogenesis in vitro through the PI3K/AKT
pathway, contributing to the stimulation of wound healing and
angiogenesis in diabetic rats in vivo (Ding et al., 2019). This
route is also reported to be involved in promoting fibroblast
proliferation and the optimization of collagen deposition
in vitro after hAT-MSC-derived exosome treatment. In vivo,
these exosomes significantly accelerated wound healing (Zhang
W. et al., 2018). Regarding AKT, Yu et al. (2020) showed
that exosomes from human BM-MSCs (hBM-MSCs) treated
with atorvastatin (ATV) activated AKT/endothelial nitric oxide
synthase (eNOS) signaling pathway to augment the angiogenesis
of endothelial cells via upregulating miR-211-3p, resulting in
accelerated wound regeneration in diabetic rats in vivo. The same
effect has been reported after treatment with exosomes from
the same origin pre-treated with serum of neonatal and adult
mice (Qiu et al., 2020). In addition to AKT, hBM-MSC-derived
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exosomes are able to activate ERK1/2 and Signal transducer and
activator of transcription 3 (STAT3), promoting the expression
of trophic factors such as cyclin D2 in vitro. This stimulates
fibroblast growth, migration and angiogenesis of endothelial cells
in vitro (Shabbir et al., 2015). Induced mesenchymal stromal cell
(iMSC) derived exosomes have also been proven to stimulate
ERK1/2 thus promoting the proliferation of HaCaTs and human
dermal fibroblasts (HDFs) in vivo (Kim et al., 2018). Moreover,
exosomes obtained from hBM-MSCs, hAT-MSCs, and hUC-
MSCs have been reported to be able to induce HaCaT and
HDF proliferation and migration in vitro by inducing crucial
wound healing-mediated growth factors (Choi et al., 2018) such
as vascular endothelial growth factor A (VEGF-A), fibroblast
growth factor 2 (FGF-2), hepatocyte growth factor (HGF) and
platelet-derived growth factor BB (PDGF-BB), which can activate
AKT, ERK, and STAT3 signaling (Hoang et al., 2020). Continuing
with ERK proteins, Wang et al. (2017) reported that hAT-MSC-
derived exosomes increased the MMP3 expression of skin dermal
fibroblasts by activating the ERK/Mitogen-activated protein
kinase (MAPK) pathway, leading to a high ratio of MMP3 to
TIMP1, which is also beneficial for ECM remodeling. These
exosomes also decreased the size of scars and increased the
ratio of collagen III to collagen I in murine incisional wounds
in vivo by preventing the differentiation of fibroblasts into
myofibroblasts and increasing the ratio of TGF-β3 to TGF-β1
(Wang et al., 2017).
Regarding scarless wound healing, several studies have
noted the role of the TGF-β/Smad signaling pathway. For
instance, Jiang T. et al. (2020) showed that hBM-MSC-
derived exosomes promoted HaCaT and HDF growth in vitro
and accelerated scarless wound healing in vivo. They found
significantly downregulated TGF-β1, Smad2, Smad3, and Smad4
expression, alongside upregulated TGF-β3 and Smad7 expression
(Jiang T. et al., 2020). Furthermore, exosomes from hUC-
MSCs reduced scar formation and myofibroblast accumulation
in a skin defect mouse model in vivo. Specifically, Fang
et al. (2016) reported that these exosomes contain specific
microRNAs such as miR-21, miR-23a, miR-125b, and miR-145
which play key roles in suppressing myofibroblast formation by
inhibiting the transforming TGF-β2/Smad2 pathway. In line with
this, Jiang L. et al. (2020). demonstrated that tumor necrosis
factor-inducible gene 6 (TSG-6) overexpressed hBM-MSC-
derived exosomes effectively ameliorated scar pathological injury,
decreased inflammatory molecular secretion and attenuated
collagen deposition in a mouse skin wound model in vivo.
The exosome treatment downregulated the expression of TGF-
β1, p-Smad2 and p-Smad3 in the scar region (Jiang L.
et al., 2020). Smad2/3 phosphorylation has also been found
markedly decreased in fibroblasts treated with hUC-MSC-
derived exosomes along with Collagen I and III and α-SMA (Hu
et al., 2020). Considering the collagen I/III ratio, Dalirfardouei
et al. (2019) reported that exosomes originating from human
menstrual MSCs (hMen-MSCs) rapidly decreased this ratio
leading to less scar formation in a diabetic mouse model and
promoting re-epithelialization, wound closure and angiogenesis
in vivo. Exosomes from hAT-MSCs exerted the same effects
by increasing gene expression of N-cadherin, cyclin-1, PCNA
and collagen I, III in vitro and collagen I and III production
in the early stage of wound healing in vivo. Interestingly, in
the late stage, exosomes inhibited collagen expression to reduce
scar formation (Hu et al., 2016). In addition, human amniotic
epithelial cell (hAEC) derived exosomes remarkably enhanced
the proliferation and migration ability of fibroblasts in vitro
and collagen I and collagen III were downregulated in these
cells through stimulating the expression of MMP-1. In vivo
wound assays also showed that exosome treatment facilitated
the wound-healing process with well-arranged collagen fibers
(Zhao et al., 2017).
Other signaling routes reported to be involved in the wound-
healing process are the poly ADP ribose polymerase 1(PARP-
1)/apoptosis-inducing factor (AIF) apoptosis pathway and Notch
signaling pathway. The first seems to suppress HaCaT apoptosis
induced with H2O2 by inhibiting nuclear translocation of
AIF and upregulating PARP-1 after treatment with hUC-MSC-
derived exosomes in vitro. In vivo experiments showed enhanced
epidermal re-epithelialization and dermal angiogenesis (Zhao
et al., 2020). Regarding the Notch signaling pathway, an in vivo
study indicated that human fetal dermal mesenchymal stromal
cell (hFD-MSC) derived exosomes could accelerate wound
closure in a mouse full-thickness skin wound model by activating
this route (Wang X. et al., 2019).
It should be noted that the administration route of exosomes
in the in vivo studies described previously are mainly intravenous
and subcutaneous injections of exosome solutions. However,
some investigations reported hydrogel development as an
efficient administration pathway. For example, a chitosan/silk
hydrogel loaded with human gingival mesenchymal stromal cell
(hG-MSC) derived exosomes accelerated skin defect healing
in vivo (Shi et al., 2017) and a thermosensitive Pluronic F-
127 (PF-127) hydrogel containing hUC-MSC-derived exosomes
significantly accelerated wound closure rate in a diabetic
animal model in vivo (Yang J. et al., 2020). Along with
oxidative hyaluronic acid and poly-e-L-lysin (denoted as FHE
hydrogel), PF-127 also significantly improved neovascularization
and re-epithelialization in diabetic rats (Wang C. et al., 2019).
Supplementary Tables 1, 2 summarize in vitro and in vivo studies
respectively.
EXOSOMES AND OXIDATIVE STRESS,
PHOTOAGING AND REJUVENATION
Some studies have analyzed whether MSC-derived exosomes can
enhance skin rejuvenation by preventing oxidative stress and
photoaging effects. Oxidative stress is a major cause of skin injury
induced by ultraviolet (UV) irradiation and other stimuli which
can damage the cellular lipids, proteins and DNA of skin cells
by promoting the production of ROS and decreasing antioxidant
enzyme activity. This results in sunburn, premature aging,
and carcinogenesis. Keratinocytes constitute a barrier against
environmental damage by modulating oxidative stress, glucose
metabolism and inflammatory mediators through the nuclear
factor E2-related factor 2 (NRF2) signaling pathway, which is a
central player in regulating the expression of antioxidant enzymes
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following skin injury or inflammation (Schäfer et al., 2012;
Wang et al., 2020). Wang et al. (2020) investigated the effects
of hUC-MSC-derived exosomes on oxidative injury in H2O2-
stimulated epidermal keratinocytes in vitro and a UV-irradiated
mouse model in vivo. They found reduced ROS generation, DNA
damage, aberrant calcium signaling and mitochondrial changes
in addition to alleviated cellular and histological responses to
inflammation and oxidation (Table 1). Furthermore, the NRF2
signaling pathway was involved in this antioxidation activity
since its knockdown attenuated the antioxidant capacities of
exosomes both in vitro and in vivo (Wang et al., 2020) (Table 1
and Supplementary Table 3).
In terms of skin rejuvenation, the ECM and especially collagen
and elastin play a crucial role in skin growth and elasticity.
Collagen is responsible for the mechanical protection of the
body, prevention of skin dehydration, elasticity maintenance,
tissue firmness and skin wrinkle minimization. Elastin is a
major structural protein of body tissue and a fibrous protein
which provides strength and natural elasticity (Kim et al., 2017).
Kim and colleagues studied the capacity of hUC-MSC-derived
exosomes to rejuvenate skin by modulating collagen production
and permeation (Kim et al., 2017; Ferreira and Gomes, 2019).
They reported stimulation of HDF migration and collagen
synthesis in vitro and promotion of collagen I and elastin
production in ex vivo human skin (Kim et al., 2017) (Table 1
and Supplementary Table 3). Interestingly, they also found
decreased MMP-1 production, which works as a collagenase
and encodes a secreted enzyme which breaks down the types
I, II, and III interstitial collagens (Tallant et al., 2010; Kim
et al., 2017). Lastly, Zhang K. et al. (2020) studied whether the
marine sponge Haliclona sp. spicules (SHSs) could effectively
enhance the skin delivery of exosomes from hUC-MSCs by
evaluating its topical application in rejuvenating photoaged
mouse skin. It was reported that the combination of exosomes
and SHSs showed significant anti-photoaging effects in mice,
including reducing microwrinkles, alleviating histopathological
changes and promoting the expression of extracellular matrix
constituents. Moreover, skin irritation tests on a guinea pig
animal model showed slight irritation (Zhang K. et al., 2020)
(Table 1 and Supplementary Table 3).
Taken together, these investigations prove the significant role
of exosomes, mainly derived from hUC-MSCs, in preventing
oxidative skin damage and promoting rejuvenation. This could
lead to the potential use of MSC-derived exosomes in the
development and application of cosmetics, although further
studies about their effects on in vivo human skin are required.
EXOSOMES AND HAIR GROWTH
Alopecia is a common medical problem which has serious
negative impacts on affected individuals. It is related to
various factors including nutritional deficiencies, hormonal
changes and drug treatment (Rajendran et al., 2017). Alopecia
areata and androgenic alopecia are challenging conditions for
dermatologists nowadays, with a lack of effective treatments.
Advanced therapies are a promising therapeutic option and have
shown good results (Martinez-Lopez et al., 2020).
Various dermatological compounds have been developed to
combat alopecia. Finasteride and minoxidil are the mainstay
treatments for alopecia. However, they only have a short-term
effect and discontinuation of treatment leads to rapid hair loss
and has known side effects (Mysore, 2012; Suchonwanit et al.,
2019; Ha et al., 2020). Autologous follicle transplantation has also
been tried, but the number of donor follicles is limited, it is an
invasive procedure and the graft survival rate largely depends
on the surgeon. Therefore, alopecia is an unsolved problem
requiring effective long-term strategies (Rajendran et al., 2017).
The hair follicle cycle is a complex process involving
alternating phases of rapid growth (anagen), regression (catagen),
and quiescence (telogen) (Alonso and Fuchs, 2006). Hair follicles
are epidermal appendages that contain both epithelial and
mesenchymal compartments. The dermal papilla (DP) is located
at the base of the hair follicle and plays a fundamental role in the
hair follicle cycle (Kishimoto et al., 2000; Rajendran et al., 2017).
AT-MSCs are able to promote the proliferation of DP cells in vitro
and promote hair growth in mice and humans (Fukuoka et al.,
2017; Ha et al., 2020).
The Wnt/β-catenin signaling and Shh signaling pathways, in
addition to the secretion of growth factors such as FGF-5 or
insulin-like growth factor-1 (IGF-1), are crucial for hair follicle
development and hair growth (Ha et al., 2020). Other routes
involved in the telogen to anagen transition include the estrogen
receptor pathway, Bone Morphogenetic Protein (BMP) signaling,
mammalian Target of Rapamycin (mTOR) signaling, FGF and
TGF-β signaling pathways (Rajendran et al., 2017).
Direct transplantation of DP cells has been tested and their
ability to induce follicles has been demonstrated (Weinberg
et al., 1993). However, cell transplantation therapy is generally
associated with the risk of tumor formation, graft rejection
and ethical concerns. DP-MSC-derived exosomes have been
reported to induce the passage from telogen to anagen, as
well as delayed transition from anagen to catagen in vivo.
Furthermore, these exosomes stimulated the expression of
β-catenin and Shh, regulators of the hair follicle cycle and the
proliferation and migration of outer root sheath keratinocytes,
increasing their entry into S and S/G1 phase. The result was
the formation of hair shafts of greater length and diameter
(Zhou et al., 2018). Moreover, Kwack et al. (2019) stated
that DP-exosomes were able to induce the development of
in vitro cultured human hair follicles and also hair growth
in vivo mice models. Interestingly, Yan et al. (2019) found 111
miRNAs that are differentially expressed between DP cells and
DP exosomes. There were 34 major miRNAs that pointed to
exosomes as regulators of hair follicle stem cell proliferation and
differentiation. Specifically, miR22-5p inhibits hair follicle stem
cell proliferation by targeting the Lymphoid enhancer-binding
factor 1 (LEF1) gene, an important regulator of the β-catenin
signaling pathway (Yan et al., 2019).
Rajendran et al. (2017) have produced the only publication to
date on MSC exosomes, where the effect of BM-MSC-derived
exosomes on hair growth was studied (Rajendran et al., 2017)
(Table 1 and Supplementary Table 3). They found that in vitro
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TABLE 1 | In vitro studies of MSC exosomes in other skin conditions.




hUC-MSCs The culture medium was
processed using a series of
centrifugation steps (300 g
for 10 min, 2,000 g for
10 min and 10,000 g for
30 min). Exosomes were
collected via
ultracentrifugation at
















hUC-MSCs The culture medium was
successively centrifuged at
400 g for 10 min, 2,000 g
for 30 min and 10,000 g for
60 min. The supernatant
was passed through a
syringe filter (0.22 µm) and
centrifuged at 100,000 g
for 120 min to pellet
exosomes. The pellet was
washed and then
centrifuged for another
120 min at the same high
speed









hUC-MSCs The culture medium was
centrifuged at 300 g for
10 min and 16,500 g for
30 min and then filtered
through a 0.22 µm filter.
The final supernatant was
then ultracentrifuged at
100,000 g for 70 min to
pellet exosomes. The pellet
was filtered through a
0.22 µm filter and

















hBM-MSCs The culture medium was
centrifuged at 2,000 g for
30 min. The supernatant
was passed through a





at 10,000 g for 1 h
Peripheral blood
mononuclear cells







hBM-MSCs The culture medium was
centrifuged 200 g for
10 min, 2,000 g for 20 min,
10,000 g for 30 min and
110,000 g for 7 h at 4◦C,
followed by filtration using a
0.22 µm filter. The culture
supernatant was collected
and ultracentrifugation was
performed with the same
sequential centrifugation
procedure. The pellet was
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TABLE 1 | Continued




hESC-MSCs The culture medium was
0.22-µm filtered and




CD4+ T cells GVHD ↑Polarization of











BM-MSCs The culture medium was
filtered through a 0.22 µm
pore size membrane and
subjected to three
continuous centrifugations
at 300 g (10 min), 1,200 g
(30 min) and 10,000 g
(45 min). Then the
supernatant was
concentrated using
100 kDa Amicon R© filter and
exosomes were isolated
with Exoquick TC kit
according to the protocol
Melanoma murine
cells












Melanoma Not characterized ↓Cell survival rate de Araujo
Farias
et al., 2018
BM-MSCs The culture medium was
centrifuged at 300 g for
10 min, at 1,500 g for
20 min and finally at
2,500 g for 20 min. The
supernatant was filtered
through a 0.2 µm syringe
filter and ultracentrifuged at
100,000 g for 60 min.
Pellets were washed and
ultracentrifuged again









hUC-MSCs Exosomes were isolated
using exoEasy Maxi kit.
Prefiltered culture medium
was mixed with a binding
buffer and added to the
exoEasy membrane affinity





and wash buffer was added




were eluted by adding
elution buffer to the spin













treatment of DP cells with these exosomes caused activation
by phosphorylation of AKT, as well as of the antiapoptotic
protein Bcl-2, thus increasing their survival and migration.
On the other hand, the expression and release of VEGF and
IGF-1 genes were significantly increased in a dose-dependent
manner by treatment with MSC-EV. These factors promote
hair growth, an increase in follicle size and hair thickness.
In vivo effects of these exosomes led to an increase in Wnt3a
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and Wnt5a signaling, so the treatment could be useful for
activating human hair follicle stem cells, resulting in anagen
initiation through Wnt/β-catenin activation (Rajendran et al.,
2017). BM-MSC exosomes significantly promoted the conversion
of telogen to anagen and increased the thickness of the dermis,
which also indirectly reflects the improvement of hair growth.
Additionally, no major organ damage was observed, indicating
that BM-MSC exosomes could be a non-toxic treatment option
(Rajendran et al., 2017).
Alopecia areata and androgenic alopecia are challenging
conditions for dermatologists nowadays, with a lack of effective
treatments. Advanced therapies are a promising therapeutic
option that have shown good results (Martinez-Lopez et al.,
2020). Although few studies have focused on the use of exosomes
to stimulate hair growth, the findings so far are promising. In
fact, a patented study points to MSC exosomes as the central
component of a pharmaceutical composition aimed at promoting
hair growth (Lim et al., 2015). It is very likely that the role of
MSC exosomes in hair follicle dynamics will become a high-
impact tool in skin regenerating cosmetics and biomedicine
(Carrasco et al., 2019).
EXOSOMES AND GRAFT VERSUS HOST
DISEASE
Graft versus host disease (GVHD) occurs when donor cells
attack host cells. There are two ways of developing GVHD: acute
GVHD (aGVHD) which appears earlier and usually remains
as a skin rash, and chronic GVHD (cGVHD) which appears
later and may affect more tissues and organs. cGVHD is
the primary cause of long-term morbidity and mortality after
allogeneic hematopoietic stem cell transplantation (Lai et al.,
2018). The epithelial target tissues affected by classic cGVHD
are the gastrointestinal tract, liver, skin, and lungs. In fact,
pulmonary complications are currently considered diagnostic
evidence of cGVHD and are characterized by a frequent lack
of response to treatment and irreversibility. However, other
systems such as the oral, esophageal, musculoskeletal, joint,
fascial, ocular and lymphohematopoietic can also be damaged.
A proposed conceptual model divides the pathophysiology of
cGVHD into three stages: early inflammation (phase 1), later
chronic inflammation, thymic injury and dysregulated B cell and
T cell immunity (phase 2), and finally tissue repair with fibrosis
(phase 3) (Zeiser and Blazar, 2017).
Firstly, the translocation of bacteria and fungi to the tissue
creates damage that causes the release of pathogen-associated
molecular patterns (PAMPs), as well as damage-associated
molecular patterns (DAMPs), leading to a cascade of activation
of toll-like receptors (TLRs), nucleotide-binding oligomerization
domain-like receptors (NOD-R) and the NOD-like receptor
protein 3 inflammasome (NLRP3) (Zeiser and Blazar, 2017). As
the intima of the vessels is damaged by inflammation, endothelial
cells are lost and the microvasculature is disorganized. In
addition, T cells are activated during the initiation phase
of chronic GVHD.
In the second stage, T cells are polarized toward type 1, type
2, and type 17 helper T (Th1, Th2, and Th17) cells. In addition,
thymic epithelial cells are lost, which are necessary for the
generation of regulatory T (Treg) cells and for positive selection
of T lymphocytes (Zeiser and Blazar, 2017). The Th17/Treg ratio
has been considered a specific marker of cGVHD progression
(Lai et al., 2018).
Lastly, platelet-derived growth factor α (PDGF-α) and TGF-β
activate fibroblasts, causing extracellular matrix production and
ultimately the sclerotic phenotype. In addition, the production of
isotype-switched immunoglobulin by differentiated B cells results
in pathogenic immunoglobulin deposition in various organs,
which contributes to organ damage and fibrosis (Zeiser and
Blazar, 2017). The chronic inflammatory state is maintained by
the Th17 cells that escaped immune regulation in the second
stage (MacDonald et al., 2017).
Due to their immunomodulatory properties, MSCs are a
promising therapy for preventing cGVHD. MSCs regulate the
Th17/Treg balance and promote transportation tolerance (Weng
et al., 2012). MSC exosomes mediate the paracrine effects of
MSCs and promote tissue repair and homeostasis recovery,
making them potential candidates for cell-free therapies (Lai
et al., 2018). MSC exosomes are able to inhibit inflammation
by suppressing the activation and migration of autoreactive T
cells. Exosomes secreted by immune and non-immune cells can
stimulate and inhibit the immune system. The effects of exosomes
on immunity include the activation of T cells, polarization of T
cells into Treg cells, immunosuppression, anti-inflammatory and
others (Wang W. M. et al., 2019).
In vivo and in vitro experiments have demonstrated the
ability of MSC exosomes to inhibit cGVHD by promoting
the expansion of Treg cells whilst inhibiting pro-inflammatory
Th17 cells (Table 1 and Supplementary Table 3). In fact,
hBM-MSCs-derived exosomes exert marked immunosuppressive
effects on cytokine production (Lai et al., 2018). Specifically,
these exosomes inhibit the expression of pro-inflammatory
cytokines such as IL-17A, a characteristic cytokine of Th17
cells. Furthermore, they are capable of inducing the production
of IL-10, a characteristic cytokine of Treg. In this way, hBM-
MSCs-derived exosomes carry out regulatory immune responses
capable of attenuating cGVHD. Also, they are a promising
therapeutic tool for treating pulmonary complications in cGVHD
(Lai et al., 2018).
Several studies reveal the effective immunomodulatory
potential of MSC exosomes for the treatment of cGVHD by
regulating Treg through different pathways, such as MYD88-
dependent signaling (Zhang et al., 2014) (Supplementary
Table 3) or by pathways dependent on antigen-presenting
cells. Furthermore, it appears that induction of Tregs mediated
by human embryonic stem cell–derived MSCs (hESC-MSCs)-
derived-exosomes requires previous T cell activation (Zhang
B. et al., 2018) (Table 1 and Supplementary Table 3). The
immunosuppressive effect of MSC exosomes has been evaluated
in a mouse model of myocardial ischemia/reperfusion injury,
renal fibrosis, liver injury, etc. (Lai et al., 2010; Lee et al., 2012;
Li et al., 2013). Furthermore, hBM-MSC-derived exosomes had
immunoregulatory effects on peripheral blood mononuclear cells
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in vitro and could prolong the survival of mice with aGVHD and
improve aGvHD damage in vivo (Fujii et al., 2018) (Table 1 and
Supplementary Table 3).
In a preliminary clinical study, a patient with resistant
grade IV aGVHD was treated with hBM-MSC-derived exosomes
(Kordelas et al., 2014) (Supplementary Table 3). The levels
of IL-1β, TNF-α, and IFN-γ produced by peripheral blood
mononucleated cells (PBMC) were reduced by more than 50%
after the last application. In this context, the clinical outcome
of aGVHD improved significantly shortly after the start of
MSC exosome therapy (Kordelas et al., 2014). Therefore, MSC-
derived exosomes may potentially provide a new and safe tool for
treating therapy-refractory GVHD and other diseases potentially
associated with inflammation (Leung, 2013).
In addition to GVHD, allograft rejection is the main reason
for the failure of organ transplantation. A novel study analyzed
the role of exosomes as RNA transport vehicles to induce
immune tolerance in patients with skin grafts. The RNA delivery
system of targeted dendritic cells (DC exosomes) was constructed
based on MSC exosomes. DC exosomes were able to induce
immune tolerance 3, 7, and 14 days after skin transplantation.
Furthermore, the long-term immune tolerance of the graft was
maintained in the murine model (Li C. et al., 2020).
EXOSOMES AND ATOPIC DERMATITIS
Chronic uncontrolled inflammatory responses are associated
with various inflammatory diseases, including allergic skin
diseases such as AD (Shin et al., 2020). Due to their
intrinsic immunosuppressive properties, MSCs are a key
element in the regulation of inflammation and therefore
in the treatment of these allergic diseases. Furthermore,
the clinical value of MSCs in AD has been confirmed in
clinical trials (phase I/IIa) (Carrasco et al., 2019). Specifically,
MSC exosomes represent an excellent alternative to MSC
cell therapy since MSC exosomes have biological functions
similar to those of parent cells, while they are more stable
and have lower immunogenicity. The anti-inflammatory and
immunomodulatory functions of MSC exosomes have been
widely described (Ha et al., 2020).
Specifically, AD is a chronic skin disease with serious
erythematous lesions and severe systemic inflammation. AD is
related to genetic, immunological and environmental factors and
its prevalence is higher in developed countries, particularly in
recent years (Sanabria-de la Torre et al., 2020). Different factors
must be taken into account in order to develop an effective
treatment against AD. On one hand, elevated levels of Th2
cytokines are associated with abnormal immune responses that
increase susceptibility to AD (Leung, 2000). On the other hand,
the abnormal expression of genes responsible for epidermal
barrier function is a crucial factor in the development of AD
(Silverberg and Silverberg, 2015). The pathogenesis of AD
includes changes in the skin barrier, abnormal immune signaling
and defective terminal differentiation of keratinocytes, leading
to decreased levels of ceramides, filaggrin and antimicrobial
peptides (Leung, 2013). Alteration of the skin barrier leads
to severe skin inflammation, allowing the entry of pathogens,
allergens and toxic environmental pollutants. Ceramides
contribute to keratinocyte differentiation and thus epidermal
barrier function (Mizutani et al., 2009). In fact, AD patients have
reduced ceramide levels (Imokawa et al., 1990).
Regarding the epidermal barrier in AD, Shin et al. (2020)
demonstrate that hAT-MSC-derived exosomes are capable of
improving the barrier functions of epidermal permeability, which
coincides with a significant increase in ceramides and a reduction
in immune responses during AD progression (Supplementary
Table 3). In addition, MSC exosomes stimulated the production
of epidermal ceramides and the formation of laminar bilayers
at the stratum granulosa-stratum corneum interface, which
contributes to the differentiation of keratinocytes and helps
form an adequate epidermal permeability barrier. Finally, MSC
exosomes were also found to activate genes associated with
keratinocyte differentiation (Shin et al., 2020). Therefore, MSC
exosomes offer a promising cell-free therapeutic option for the
treatment of AD, thanks to their role in the de novo synthesis
of ceramides, in the activation of genes involved in keratinocyte
differentiation, lipid metabolism, cell cycle as well as their
intervention in the regulation of the immune response.
Regarding their role as mediators of inflammation, hAT-
MSC-derived exosomes significantly decreased the production
of pro-inflammatory cytokines [Interleukin (IL) −4, 5, 13, 17],
tumor necrosis factor α (TNF-α), interferon gamma (IFN-
γ) and thymic stromal lymphopoeitin (TSLP) in the murine
model of AD in a dose-dependent manner. Since TSLP is also
known to be an important itch inducer, this result implied that
AT-MSC exosomes helped reduce itching (Shin et al., 2020)
(Supplementary Table 3). Moreover, MSC exosomes promote
anti-inflammatory polarization of M2 macrophages and reduce
pro-inflammatory polarization of M1 macrophages. In this way,
MSC exosomes reduce the expression of Th2 cytokines, including
IL-4, IL-13, IL-23, and IL-31, therapeutic targets for AD (Cho
et al., 2018; Ha et al., 2020; Shin et al., 2020). In fact, Cho
et al. (2018) studied the intravenous (IV) and subcutaneous
(SC) administration of hAT-MSC-derived exosomes finding AD
symptoms significantly decreased in a dose-dependent manner in
both murine models (Supplementary Table 3). These exosomes
were able to reduce the clinical score, the numbers of MCs,
CD86+ cells and CD206+ cells in the dermal tissue, as
well as the mRNA levels of associated inflammatory factors
(Cho et al., 2018).
EXOSOMES AND PSORIASIS
Psoriasis is one of the most common skin diseases, affecting
over 125 million people worldwide. It is a chronic skin disease
represented by red squamous plaques that usually appear on the
elbows, knees, sacroiliac region, nails, and scalp. Its histological
features are characterized by epidermal hyperplasia, increased
angiogenesis, and immune cell infiltration (Zhang Y. et al., 2020).
There is also an extensive list of comorbidities associated with this
disease (including Crohn’s disease, psoriatic arthritis, atherogenic
dyslipidemia, hypertension, diabetes, as well as increased carotid
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intima-media thickness) (Martinez-Lopez et al., 2018; Sanabria-
de la Torre et al., 2020). It is fundamentally associated with
immunological and genetic factors. Treatments are varied and
tend to be aimed at reducing skin lesions; this is a current area of
research. The therapeutic effects of MSCs on psoriasis have been
reported in experimental studies and clinical cases (Chen et al.,
2016; De Jesus et al., 2016; Sah et al., 2016). In two clinical cases
of psoriasis vulgaris treated with MSCs, both of them remained
relapse-free for 4 or 5 years.
As mentioned above, MSC exosomes have therapeutic
effects on various relapsing inflammatory disorders such as
AD and cGVHD. Accumulative evidence has indicated that
MSC exosomes exhibit potent immunomodulatory effects by
regulating the activation of immune cells and inhibiting the
expression of various inflammatory cytokines (Kordelas et al.,
2014; Cho et al., 2018; Lai et al., 2018).
In fact, Zhang Y. et al. (2020) demonstrated that hUC-
MSC-derived exosomes prevented the progression and reduced
the severity of psoriasis by regulating immune cells, through
inhibiting in vitro the maturation and activation of DCs and
Th17 cells, along with HaCaTs. In addition, treatment with
these exosomes effectively blocked the induction of inflammatory
cytokines and reduced both histopathological symptoms and
immune responses in a mouse model in vivo (Table 1 and
Supplementary Table 3).
EXOSOMES AND MELANOMA
The tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a member of the TNF family with a selective effect
on cancer cells. As a promising agent for cancer therapy, TRAIL
can induce cell apoptosis by interaction with its receptors, death
receptor 4 and 5 (DR4 and DR5) on tumor cells. Human
melanoma cells express TRAIL DR5 (Kurbanov et al., 2005).
Murine melanoma cells (B16) express a moderate level of TRAIL-
R on their cell surface (Dufour et al., 2017). Mueller et al.
demonstrated that TRAIL-modified MSCs (MSC-TRAIL) could
effectively induce apoptosis in sensitive advanced colorectal
carcinoma cells in vitro and also inhibit tumor growth in
animal models (Mueller et al., 2011). Yuan et al. (2017) showed
that exosomes derived from MSC-TRAIL (TRAIL exosomes)
were capable of inducing effective apoptosis in a wide range
of cancer cell lines including lung adenocarcinoma, primary
normal human bronchial epithelial cells, renal cancer cells,
breast adenocarcinoma and neuroblastoma cell lines in vitro.
Compared to recombinant soluble TRAIL, TRAIL exosomes
exert a greater killing efficiency of cancer cells. Due to the
fluidic nature of the bilayer membrane, the lipid membrane
of TRAIL exosomes allows higher TRAIL oligomerization and
subsequently higher clustering of its receptors (Yuan et al.,
2017). Also, the low pH condition of tumor microenvironment
potentially influenced exosome trafficking and uptake by cancer
cells (Parolini et al., 2009).
In a recent study, Shamili et al. (2018) investigated the anti-
tumor effect of TRAIL exosomes, drawing on the combined use
of tumor-specific cytotoxicity of TRAIL and intrinsic properties
of BM-MSC-derived exosomes on tumor cells. Specifically, the
anti-tumor activity of MSC exosomes and TRAIL exosomes was
analyzed in vitro and in three in vivo models (Table 1 and
Supplementary Table 3).
In vitro analysis (Table 1) consisted of a co-culture of the
exosomes with murine melanoma cells (B16F0 cells). There was
a significant difference in cell viability between cells treated
with TRAIL exosomes and those treated with MSC exosomes.
Specifically, TRAIL exosomes and MSC exosomes induced
11.93 and 4.69% apoptosis in B16F0 cells, respectively (Shamili
et al., 2018). To evaluate the in vivo anti-tumor activity of
these exosomes (Supplementary Table 3), three models of
melanoma tumor-bearing mice were developed. In the co-
delivery model, tumor cells were co-injected with exosomes
and in the non-co-delivery model exosomes were injected
after tumor appearance in a single dose or in multiple doses.
The co-delivery model resulted in a delayed appearance of
the tumor for 6 days and a reduction in size. The non-
co-delivery administration with a single dose showed anti-
tumor activity in early days, delayed tumor growth and an
increased life expectancy of 4 days. Finally, non-co-delivery
administration with multiples doses also resulted in a significant
reduction of tumor size and an increased life expectancy
of 8 days. Delayed tumor growth was higher compared to
the single doses. In summary, it was demonstrated that
MSC exosomes and TRAIL exosomes have potential capacity
as targeted cancer treatment, with the best option being
TRAIL exosomes. Specifically, the best administration option
was delivery after tumor appearance of TRAIL exosomes
in multidose. These exosomes could be exploited for drug
delivery purposes to deliver therapeutic agents. In addition, this
study highlights the possibility of combining TRAIL exosomes
and chemotherapeutics as a promising anti-tumor strategy
(Shamili et al., 2018).
de Araujo Farias et al. (2018) investigated the role of
exosomes derived from irradiated MSCs (irMSC exosomes) A375
melanoma cell line in vitro and in tumor growth and metastasis
retardation after treatment with MSC + radiotherapy in vivo
(Table 1 and Supplementary Table 3). In this study, the authors
report the possible implication of exosomes cargo, specifically
annexins (ANXA1 and ANAX2), integrins (ITGB1 and ITGA3),
fibronectin 1 (FN1), catenin β1 (CTNNB1) and apolipoprotein
H (APOH), in their suppressive action on A375 cells survival.
Regarding in vivo outcomes, the ability of MSCs to accumulate
at tumor sites makes them extremely attractive for targeted
cancer therapy; in addition, the tumor tropism of MSCs has
been reported to increase with radiation therapy (Kim et al.,
2010). MSCs combined with radiation therapy enhances the
effects of radiation on the metastatic spread of melanoma cells
and exosome-derived factors could be involved in these effects
(de Araujo Farias et al., 2018). MSC exosomes appear to bind
to specific membrane microdomains in tumor cells, amplifying
the action of radiation therapy, stimulating tumor cell death,
thus increasing the sensitivity of cells to radiation and promoting
systemic effects (Kim et al., 2010). Radiation therapy itself may
not be systemic, although it could contribute to a systemic effect
when used in combination with MSCs due to the ability of irMSC
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exosomes to increase the control of tumor growth and metastasis
(de Araujo Farias et al., 2018).
DISCUSSION
Exosomes derived from MSCs are characterized by having
immunomodulatory and regenerative properties and because of
this they have gained much attention as a new potential cell-free
approach in this field by overcoming the inherent limitations of
the use of MSCs in the treatment of inflammatory skin diseases.
Although the role of MSC exosomes in wound healing has been
discussed (Roşca et al., 2018; Hu et al., 2019; Casado-Díaz et al.,
2020), exosomes have been reported to play crucial roles in other
skin conditions. In the present review, the function of MSC
exosomes not only in wound healing and skin regeneration but
also in oxidative stress and rejuvenation, hair growth, melanoma
and autoimmune disorders such as GVHD, psoriasis and AD
has been analyzed.
In this context, different signaling routes and molecules where
exosomes are implicated have been proposed in the available
bibliography, depending on the specific study. Regarding wound
healing and skin regeneration, the most-reported signaling
pathways include Wnt/β-catenin, PI3K/AKT, ERK, and TGF-
β/Smad. Wnt/β-catenin and AKT cascades seem to participate
in hair growth as well. Different miRNA and other molecules
may also be involved. The NRF2 defense system is related
to the oxidative stress process. With respect to autoimmune
disorders, MSC exosomes seem to reduce pro-inflammatory
cytokines and to promote induction of regulatory T cells. Finally,
in melanomas, the administration of exosomes is capable of
reducing tumor growth and size and promoting life span of
in vivo models.
In addition to the mechanism of action, the origin of the
exosomes can also affect their role. It is important to analyze
the differences between fetal and adult MSC-derived exosomes.
Firstly, regarding the source of MSCs, several aspects have
to been taken into account. Commonly used adults MSCs
as source of exosomes include AT-MSCs and BM-MSCs. AT-
MSCs are usually isolated from left over biological material
generated during liposuction, lipoplasty, or lipectomy procedures
while BM-MSCs are obtained from bone marrow aspirate, an
invasive and painful procedure (Hass et al., 2011). The most
used fetal MSC source of exosomes is UC-MSCs. Other fetal
MSCs include ESC-MSCs and FD-MSCs. Advantages derived
from the use of these MSCs over adult MSCs comprise their ready
availability and their obtaining from no invasive procedures.
Furthermore, fetal MSCs have shown improved proliferative
capacity, life span and differentiation potential (Hass et al., 2011).
Considering the role of exosomes derived from both fetal and
adult MSCs, several points need to be highlighted. Regarding
fetal MSC-derived exosomes, UC-MSC-derived exosomes are
implicated in wound healing, oxidative stress defense process,
rejuvenation and psoriasis. No other source, fetal or adult, of
exosomes has been used for testing its role in the oxidative stress
defense process, rejuvenation and psoriasis. Regarding wound
healing, FD-MSCs and iMSC (from Wharton’s Jelly derived
IPSCs) have also been used. ESC-MSC-derived exosomes have
showed beneficial effects in GVHD. Concerning adult MSC,
AT-MSC-derived exosomes are implicated in wound healing
and AD. No other source of MSC has been used for testing
exosome’s role in AD. Among adult MSCs, just BM-MSC-
derived exosomes have been shown improvements on acute,
chronic and refractory GVHD, melanoma and hair growth. Men-
MSC- and G-MSC-derived exosomes have improved wound
healing outcomes. Comparative studies are lacking about specific
differences between exosomes from fetal MSC and from
adult MSC.
Regarding the possible clinical translation of exosomes, it
is essential to determine the optimal source of MSCs. Cell
senescence due to culture passages and time can alter the
exosome cargos and therefore their properties. In this sense,
iMSC is a strategy for exosome production with several
advantages. Thus, established iPSCs can expand indefinitely and
easily become iMSCs within 20 days. Moreover, the in vitro
growth and differentiation potential of MSCs is affected by
the culture period, the donor’s age and the donor’s health
status, factors that are also resolved with the use of iMSC.
Furthermore, iMSCs avoid ethical problems and immune
rejection (Kim et al., 2018). In this sense, MSCs from oral
cavities are more easily harvestable than other anatomic sites
and have shown a great plasticity toward the main lineages,
specifically toward bone tissues. Human periapical inflamed cyst
in particular represents a promising source of MSCs because
of the reduced ethical and biological issues as it is usually
considered biological waste (Spagnuolo et al., 2018; Tatullo
et al., 2019). Moreover, it is important to determine the optimal
culture conditions. As mentioned throughout this review, it is
feasible to condition MSC media in order to enhance determined
exosome features depending on the study. In addition, the
methodology for isolating and purifying exosomes must be highly
controlled and optimized.
However, due to the lack of clinical trials, the heterogeneity
of MSC products prepared by different laboratories, diverse
strategies of MSC isolation and absence of standardization
across groups, it is difficult to achieve the MSC exosome
bench to bedside translation as any new therapeutic platform
requires the establishment of GMP conditions and standards
for production. In case of exosomes, there are some limitations
to overcome. These limitations include large-scale production,
downstream purification methods, and quality control systems
(Jafari et al., 2020). Regarding limitations on exosome’s
production, studies about scaling up cell culture have focused
on technologies to maximize surface area (Colao et al., 2018).
Hollow-fiber bioreactors, which are high-density systems for
culturing cells, allow continuously production of exosomes
for more than 10 weeks, without splitting or subculturing
the cells, increasing the exosome production from 10 to 100
fold (Whitford et al., 2015; Colao et al., 2018; Jafari et al.,
2020). Other strategies include genetic manipulation of MSCs
for producing an immortalized cell line, which continuously
produced exosomes or the design of PEGylated wells for the
aggregation of cells and the formation of MSC spheroids to
enhance cell-to-cell communication (Jafari et al., 2020). Once
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scaling up cell culture of MSC for large-scale production of
exosomes is achieve, it is necessary to define them physically,
biochemically and functionally by quantifiable features and
using reproducible and standardized assays. Members of the
Society for Clinical Research and Translation of Extracellular
Vesicles Singapore (SOCRATES), the International Society for
Extracellular Vesicles (ISEV), the International Society for Cell
and Gene Therapy (ISCT) and the International Society of
Blood Transfusion (ISBT) have proposed specific harmonization
criteria for MSC-small EVs (sEVs) to facilitate data sharing
and comparison (Witwer et al., 2019). Precisely, MSC-sEVs
should be defined by quantifiable metrics to identify the
cellular origin of the sEVs in a preparation, presence of lipid-
membrane vesicles and the degree of physical and biochemical
integrity of the vesicles. Therefore, specifications related to
purity, identity, quantity, potency, and sterility need to be
defined in accordance with the regulations for pharmaceutical
manufacturing (Gimona et al., 2017). Quality can be assessed
by producing them through validated procedures. Sterility
testing is achieved by stablished protocols for detection of
microbiological and endotoxin contaminations. Potency issues
relies on more molecular biology and physiology information.
In fact, qualified potency assays in disease-relevant in vitro and
in vivo models are necessary to elucidate their mechanism of
action (Gimona et al., 2017; Jafari et al., 2020). Limitations on
downstream purification and characterization methods make
it difficult to determine purity and identity of exosomes. In
these aspects, heterogeneity is a critical issue. Research efforts
are focus on strategies to improve the isolation of exosomes,
although there is no consensus on the most suitable method
for exosomes enrichment and purification (Gimona et al., 2017).
Some recent technologies include serial filtration, tangential
flow filtration (TFF) or polymer precipitation (Gimona et al.,
2017; Colao et al., 2018; Jafari et al., 2020). Standardized GMP-
compliant TFF systems are available on the market, offering
the possibility of validated process control. Another promising
strategy comprises sequential filtration followed by affinity-
based chromatography that specific surface proteins (Jafari
et al., 2020). Considering identity of exosomes, the ISEV has
established a set of criteria for their proteomic identification
with a minimal list of requirements: exosomes should (1) have
transmembrane proteins to provide evidence of a membrane;
(2) have cytosolic proteins to provide evidence of membrane-
or receptor-binding; (3) be free of protein impurities from
intracellular compartments not associated with the plasma
membranes or endosomes; and (4) be free of co-isolating
extracellular proteins (Colao et al., 2018). Characterization
approaches of exosomes include nanoparticle tracking analysis
(NTA) and dynamic light scattering (DLS) for size distribution
and zeta potential determination, ELISA assay, Western blotting,
and flow cytometry for exosome protein analysis and quantitative
reverse transcription-PCR (qRT-PCR), mass spectrometry, and
miRNA array for exosome content determination (Jafari et al.,
2020). However, since exosomes are still difficult to purify,
minimal acceptance and release criteria include these statements:
(1) MSCs display an ISCT-compliant surface marker profile at
the time of secretome harvest; (2) EVs within the secretome
fraction must comply with the minimal criteria of ISEV, at least
for a number of membrane markers; (3) The size range should
be in the range of exosomes (50–150 nm) and (4) Sterility
and endotoxin levels must comply with regulatory requirements
(Gimona et al., 2017).
Another factor to consider is the in vivo administration of
exosomes. As has been shown, subcutaneous and intravenous
are the most frequently used administrations although it is
possible to deliver them through different kinds of hydrogels.
In this context, scaffolds have recently gained much attention.
In fact, the geometrical and mechanical properties of scaffolds
are able to influence the secretome, interactome and cell
behavior (Ballini et al., 2017). Computer-aided design (CAD)
has emerged as a promising strategy for biomimetic scaffold
manufacturing as it allows the development of standardized
design to test different types of scaffolds by reducing bias
during measurements (Marrelli et al., 2016; Ballini et al., 2017).
Thus, it is important to optimize the application of EVs
for skin wound healing. Therefore, it would be convenient
to optimize and analyze the advantages and disadvantages
of the different application methodologies for each specific
clinical objective.
In conclusion, the currently available data in this field
shows how MSC exosomes can improve critical parameters
of preclinical and clinical models of several skin conditions,
including wound healing, oxidative stress, photoaging and
rejuvenation, AD, psoriasis, GVHD and melanoma. Exosomes
stimulate the migration and proliferation of fibroblast and
keratinocytes, promote angiogenesis, collagen synthesis, re-
epithelization and wound closure in wound healing, stimulate
hair growth and have immunoregulatory effects on inflammatory
skin diseases. Regarding oxidative stress, they are able to
decrease ROS generation and DNA damage. Lastly, in melanoma,
exosomes reduce tumor growth and promote life span. However,
very few studies have reported their role on human skin
disease models. Kwon et al. (2020) conducted a 12-week
prospective, double-blind, randomized, split-face, comparative
study to evaluate the clinical efficacy of application of hAT-
MSC exosomes after fractional CO2 laser in the treatment of
facial acne scars. The application of exosomes treatment yielded
more favorable responses, a shorter recovery time, and fewer
side-effects (Kwon et al., 2020). Regarding clinical trials, to date
there are only two about MSC exosome treatment on humans
(NCT04173650 and NCT04213248). The first trial will analyze
the impact of MSC exosomes on dystrophic epidermolysis
bullosa human wounds and the second their effect on dry eye
symptoms in patients with cGVHD. However, both are still in the
recruitment phase.
Therefore, further research is required for a
better understanding of the molecular mechanisms
underlying the action and therapeutic potency of
MSC exosomes in the clinical context. In order to
assess their clinical translation, methods for large-scale
production should be optimized and standardized,
including the source of MSCs, their isolation and
culture conditions as well as the administration protocols
for exosomes.
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GLOSSARY
Glossary: AD, atopic dermatitis; AT-MSCs, adipose tissue mesenchymal stromal cells; aGVHD, acute graft versus host disease;
AKT, protein kinase B; AIF, apoptosis-inducing factor; Ang-2, angiotensin-2; ANX, annexin; APOH, apolipoprotein H; ARG,
arginine; ATV, atorvastatin; BM-MSCs, bone marrow mesenchymal stromal cells; BMP, bone morphogenetic protein signaling;
CAD, computer-aided design; CCL20, C-C motif chemokine ligand 20; CTNNB1, catenin β1; cGVHD, chronic graft versus host
disease; CXCL12, C-X-C motif chemokine 12; DAMPs, damage-associated molecular patterns; DCs, dendritic cells; DP, dermal
papilla; DP-MSCs, dermal papilla mesenchymal stromal cells; DR, death receptor; ECM, extracellular matrix; ERK, extracellular
signal-regulated kinase; EVs, extracellular vesicles; eNOS, endothelial nitric oxide synthase; ESCRT, endosomal sorting complex
required for transport; Exos, exosomes; FD-MSCs, fetal dermal mesenchymal stromal cells; FGF, fibroblast growth factor; FN1,
fibronectin 1; GMP, good manufacturing practice; G-MSCs, gingival mesenchymal stromal cells; GVHD, graft versus host disease;
HaCaTs, human cultured keratinocytes; hAD-MSCs, human adipose tissue mesenchymal stromal cells; hAECs, human amniotic
epithelial cells; hBM-MSCs, human bone marrow mesenchymal stromal cells; HDFs, human dermal fibroblasts; hESC-MSCs, human
embryonic stem cell–derived MSCs; HGF, hepatocyte growth factor; HO-1, heme oxygenase 1; hsp, head shock protein; hUC-MSCs,
human umbilical cord mesenchymal stromal cells; HUVECs, human umbilical vein endothelial cells; IFN-γ, interferon gamma; IGF,
insulin-like growth factor; IL, interleukin; iMSCs, induced mesenchymal stromal cells; iNOS, inducible nitric oxide synthase; irMSCs,
irradiated mesenchymal stromal cells; ISBT, International Society of Blood Transfusion; ISCT, International Society for Cell and
Gene Therapy; ISEV, International Society of Extracellular Vesicles; ITG, integrin; Keap1, Kelch-like ECH-associated protein 1; KGF,
keratinocyte growth factor; LATS, large tumor suppressor; LEF1, lymphoid enhancer-binding factor 1; MALAT1, metastasis associated
lung adenocarcinoma transcript 1; MAPK, mitogen-activated protein kinase; Men-MSCs, menstrual blood mesenchymal stromal
cells; MMPs, matrix metalloproteinases; MSCs, mesenchymal stromal cells; MSC-TRAIL, tumor necrosis factor-related apoptosis-
inducing ligand modified mesenchymal stromal cells; mTOR, mammalian target of rapamycin; MVBs, multivesicular bodies; MWCO,
molecular weight cutoff; NLRP3, NOD-like receptor protein 3 inflammasome; NOD-R, nucleotide-binding oligomerization domain-
like receptors; NQO1, NAD(P)H quinone dehydrogenase 1; NRF2, nuclear factor E2-related factor 2; PAMPs, pathogen-associated
molecular patterns; PBS, phosphate-buffered saline; PARP-1, poly (ADP ribose) polymerase 1; PCNA, proliferating cell nuclear
antigen; PDGF-BB, platelet-Derived Growth Factor BB; PDGF-α, platelet-derived growth factor α; PF-127, pluronic F-127; PI3K/AKT,
phosphatidylinositol 3-kinase/protein kinase B pathway; PTEN, phosphatase and tensin homolog; ROS, reactive oxygen species;
α-SMA, α-smooth muscle actin; SHSs, Haliclona sp. spicules; STAT3, signal transducer and activator of transcription 3; SOCRATES,
Society for Clinical Research and Translation of Extracellular Vesicles Singapore; Th, helper T cells; TGF-β1, transforming growth
factor β1; TGF-β3, transforming growth factor β3; TIMPs, tissue inhibitor of matrix metalloproteinases; TLRs, toll-like receptors;
TNF-α, tumor necrosis factor α; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; Tregs, regulatory T cells; TSG-
6, tumor necrosis factor-inducible gene 6 protein; TSLP, thymic stromal lymphopoeitin; UC-MSCs, umbilical cord mesenchymal
stromal cells; UV, ultraviolet; VEGF-A, vascular endothelial growth factor A; YAP, yes-associated protein.
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